gip and glp 1 receptor agonist Tirzepatide's Unique Mechanism of Action gip and glp-1 receptor agonist
Description
Patients currently using compounded semaglutide or tirzepatide should discuss transitioning to FDA approved formulations with their healthcare provider
But there was no link between GLP-1RAs and an increased risk of cancer overall in a meta-analysis that included 37 relevant multiple dose-escalation
Weivoda MM, Chew CK, Monroe DG, Farr JN, Atkinson EJ, Geske JR, et al
M., Saikia, M
Considering the reported CV findings, cardiologists are qualified to take the lead in adopting CV risk mitigations strategies as a part of comprehensive management strategies in collaboration with endocrinologists/diabetologists
